Saturday, September 12, 2015

HCV/Hepatitis C Drug Pipeline

FDA Approved Medications

YearBrandGenericGenotype (SVR)
YearBrandGenericGenotype (SVR)
1991Intron-AInterferon-alfa-2b
1996Roferon-AInterferon-alfa-2a
1997InfergenConcensus Interferon


All Standard Interferon SVR Rates (approximately):Genotype 1 (9%) Genotype 2, 3 (30%)
1998RebetronIntron-A plus RibavirinGenotype 1 (29%) Genotype 2, 3 (62%)
2001 Peg-IntronPegInterferon-alfa-2bGenotype 1 (14%) Genotype 2, 3 (47%)
2001Peg-Intron / RibavirinPegInterferon-alfa-2b / RibavirinGenotype 1 (41%) Genotypes 2—6 (75%)
2002Pegasys PegInterferon-alfa-2aGenotype 1 (28%) Genotype 2, 3 (56%)
2003Pegasys / RibavirinPegylated alfa-2a / RibavirinGenotype 1 (51%) Genotypes 2—6 (70%) Genotype 2, 3 (82%)
2011 Victrellis / PEG / RBV Boceprevir / PEG / RBVGenotype 1 (66%)
2011Incivek / PEG / RBVTelaprevir / PEG / RBVGenotype 1 (79%)
2013Olysio / PEG / RBV Simeprevir / PEG / RBVGenotype 1 (Up to 80%)
2013Sovaldi / PEG / RBV Sofosbuvir / PEG / RBVGenotype 1 (Up to 92%) Genotype 4 (92%)
2013Sovaldi / RBVSofosbuvir / RBVGenotype 2 (Up to 100%) Genotype 3 (Up to 91%)
2014Sovaldi / Olysio / RBV Sofosbuvir / Simeprevir / RBVGenotype 1 (Up to 92%)
2014HarvoniSofosbuvir / LedipasvirGenotype 1 (Up to 100%)
2014VIEKIRA PAKOmbitasvir, Paritaprevir/Ritonavir, Dasabuvir with/without RibavirinGenotype 1 (Up to 100%)
2015DaklinzaDaclatasvir for use with SofosbuvirGenotype 3 (Up to 98%)
2015TechnivieOmbitasvir, Paritaprevir and Ritonavir plus RibavirinGenotype 4 (Up to 100%)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.